Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: BGLC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.35% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.91 | 52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 |
52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.86% | Operating Margin (TTM) -27.47% |
Management Effectiveness
Return on Assets (TTM) -14.05% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1581259 | Price to Sales(TTM) 0.54 |
Enterprise Value 1581259 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 1796600 | Shares Floating 1240011 |
Shares Outstanding 1796600 | Shares Floating 1240011 | ||
Percent Insiders 51.11 | Percent Institutions 0.88 |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
As of this writing, there is no publicly traded US stock with the name BioNexus Gene Lab Corp Common stock. Therefore, a historical overview cannot be provided. The remainder of this output will be based on what information *would* be provided if such a company existed.
Core Business Areas
- Genetic Testing Services: Offers a range of genetic tests for disease risk assessment, personalized medicine, and ancestry analysis.
- Research and Development: Focuses on developing new genetic tests and diagnostic tools.
- Bioinformatics Services: Provides data analysis and interpretation services for genetic data.
Leadership and Structure
Hypothetically, the leadership team would consist of a CEO, CFO, CSO, and other key executives. The organizational structure would likely be hierarchical, with distinct departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Disease Risk Assessment Tests: Genetic tests that assess an individual's risk for developing various diseases. Market share is hypothetical, and competitors would include companies like 23andMe (pending testing capabilities) and Myriad Genetics (MYGN). Let's assume 15% market share and $50M revenue.
- Personalized Medicine Tests: Genetic tests that guide treatment decisions based on an individual's genetic makeup. Competitors could be companies like Foundation Medicine (owned by Roche). Let's assume 10% market share and $30M revenue.
- Ancestry Testing: Genetic tests to determine ancestral origin. Competitors could be companies like 23andMe and AncestryDNA. Let's assume 2% market share and $5M revenue.
Market Dynamics
Industry Overview
The genetic testing industry is growing rapidly, driven by technological advancements, increasing awareness of personalized medicine, and decreasing costs of genetic sequencing.
Positioning
Hypothetically, BioNexus Gene Lab Corp Common stock would be positioned as an innovative provider of genetic testing services, focusing on accuracy and personalized insights.
Total Addressable Market (TAM)
The global genetic testing market is projected to reach $30 billion by 2030. BioNexus Gene Lab Corp Common stock, if it existed, would be positioned to capture a portion of this market through strategic partnerships and innovative product development.
Upturn SWOT Analysis
Strengths
- Proprietary genetic testing technology
- Strong research and development capabilities
- Experienced management team
Weaknesses
- Limited brand recognition
- High marketing costs
- Reliance on third-party suppliers
Opportunities
- Expansion into new geographic markets
- Development of new genetic tests
- Strategic partnerships with healthcare providers
Threats
- Increased competition
- Regulatory changes
- Data privacy concerns
Competitors and Market Share
Key Competitors
- Myriad Genetics (MYGN)
- 23andMe (Private)
- Invitae (NVTA)
Competitive Landscape
Hypothetically, BioNexus Gene Lab Corp Common stock would need to differentiate itself through innovative technology, superior customer service, or strategic partnerships to compete effectively.
Major Acquisitions
GeneData Insights
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded genetic testing capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical: Fast growth in initial years, followed by steady growth.
Future Projections: Hypothetical: Projected revenue growth of 10-15% per year.
Recent Initiatives: Hypothetical: Launch of a new genetic test for early cancer detection.
Summary
BioNexus Gene Lab Corp Common stock, if real, would be a promising player in the genetic testing industry with strong growth potential. Its success depends on continued innovation, effective marketing, and strategic partnerships. It faces increasing competition and regulatory scrutiny, which it must navigate carefully to maintain its market position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical market research reports
- Analyst estimates (simulated)
- Company press releases (simulated)
Disclaimers:
This analysis is based on a hypothetical company and simulated data. It is for illustrative purposes only and should not be considered investment advice. The company, BioNexus Gene Lab Corp Common stock, does not actually exist.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.